Registry study identifies significant SMN risk in childhood cancer survivors, suggesting enhanced monitoring is needed.
SMN risk remains significant for childhood cancer survivors, particularly for CNS and solid tumour cases, highlighting the need for tailored surveillance and further research on the strategies to mitigate long-term adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Halme et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: